AMSBIO announces optimized freezing solutions for clinical application of cell therapy products

AMSBIO announce new additions and certifications for their market-leading range of clinical grade, chemically defined cryopreservation excipient solutions - STEM-CELLBANKER® and HSC-BANKER®.

AMSBIO announces optimized freezing solutions for clinical application of cell therapy products

STEM-CELLBANKER® DMSO Free GMP grade is a new chemically defined freezing solution that does not contain DMSO as an anti-freezing agent. It was developed for customers who prefer not to use DMSO-containing cryopreservation solution due to the intended application of the samples. STEM-CELLBANKER® DMSO Free GMP grade is manufactured in compliance with JPN, EU, US, and PIC/S GMP guidelines.

STEM-CELLBANKER® is a chemically defined freezing media optimized for stem cells and iPS cells storage, as well as fragile primary cells. Published data supports its ability to cryopreserve organoids and tissues to allow the recovery of viable cells. STEM-CELLBANKER® GMP grade is manufactured in compliance with JPN, EU, US, and PIC/S GMP guidelines. Free from animal derived components this popular cryopreservation medium contains only chemically defined USP, EP and JP grade ingredients. Available in both DMSO containing and DMSO-Free formulations, STEM-CELLBANKER® is an optimal freezing solution for basic research and is finding widespread use in the clinical application of cell therapy products.

Manufactured to be completely free of serum and animal derived components, HSC-BANKER® contains only European or US Pharmacopoeia graded ingredients making it highly suitable for storage of hematopoietic stem cells developed for cell therapy applications.

Recently the master files of HSC-BANKER were accepted by the Center for Biologics Evaluation and Research (CBER) within the US FDA (Food and Drug Administration). Master files are submissions to the FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. Beneficially they allow researchers to reference material without disclosing Master file contents to those parties.

HSC-BANKER® is supplied ready-to-use and requires no special devices, such as a controlled rate freezer, in order to achieve consistently high viabilities following resuscitation from cryopreservation, even over extended long-term storage. HSC-BANKER® significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability after freeze-thaw. Evaluated for endotoxins, pH, osmolarity and mycoplasma contaminants to ensure GMP equivalent quality. HSC-BANKER® is part of the CELLBANKER® range of cryopreservation media for cells, organoids and tissues.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2020, September 08). AMSBIO announces optimized freezing solutions for clinical application of cell therapy products. AZoLifeSciences. Retrieved on November 24, 2020 from https://www.azolifesciences.com/news/20200908/AMSBIO-announces-optimized-freezing-solutions-for-clinical-application-of-cell-therapy-products.aspx.

  • MLA

    AMS Biotechnology. "AMSBIO announces optimized freezing solutions for clinical application of cell therapy products". AZoLifeSciences. 24 November 2020. <https://www.azolifesciences.com/news/20200908/AMSBIO-announces-optimized-freezing-solutions-for-clinical-application-of-cell-therapy-products.aspx>.

  • Chicago

    AMS Biotechnology. "AMSBIO announces optimized freezing solutions for clinical application of cell therapy products". AZoLifeSciences. https://www.azolifesciences.com/news/20200908/AMSBIO-announces-optimized-freezing-solutions-for-clinical-application-of-cell-therapy-products.aspx. (accessed November 24, 2020).

  • Harvard

    AMS Biotechnology. 2020. AMSBIO announces optimized freezing solutions for clinical application of cell therapy products. AZoLifeSciences, viewed 24 November 2020, https://www.azolifesciences.com/news/20200908/AMSBIO-announces-optimized-freezing-solutions-for-clinical-application-of-cell-therapy-products.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
You might also like... ×
Total nucleic acid extraction for pathogen detection